BR0100878A - Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matriz - Google Patents
Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matrizInfo
- Publication number
- BR0100878A BR0100878A BR0100878-1A BR0100878A BR0100878A BR 0100878 A BR0100878 A BR 0100878A BR 0100878 A BR0100878 A BR 0100878A BR 0100878 A BR0100878 A BR 0100878A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- imidazolidine
- oxo
- carboxylic acid
- matrix metalloproteinases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
Abstract
Patente de Invenção: "COMPOSTOS DE HIDROXAMIDAS DOáCIDO 2-OXO-IMIDAZOLIDINO-4-CARBOXìLICO QUE INIBEMMETALOPROTEINASES DE MATRIZ". A presente invençãorefere-se a um composto de fórmula em que R^ 1^, R^ 2^, R^ 3^ eR^ 4^ são como definidos acima, e os seus sais e solvatosfarmaceuticamente aceitáveis, que são úteis, por exemplo, comoinibidores de metaloproteinases de matriz. A presente invençãotambém é dirigida a composições farmacêuticas compreendendoesses compostos e a métodos de tratamento de doenças tais comoosteoartrite, artrite reumatóide, câncer, osteoporose, ulceração detecidos, restenose, doença peridontal, inflamação, epidermólisebulhosa, esclerite, síncope, doença de Alzheimer, e outrassemelhantes, caracterizadas por atividade inapropriada demetaloproteinases de matriz. Também são descritos processos paraa síntese de compostos de formula (I).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18889200P | 2000-03-13 | 2000-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0100878A true BR0100878A (pt) | 2001-10-30 |
Family
ID=22694989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0100878-1A BR0100878A (pt) | 2000-03-13 | 2001-03-12 | Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matriz |
Country Status (10)
Country | Link |
---|---|
US (2) | US6458822B2 (pt) |
EP (1) | EP1134215B1 (pt) |
JP (1) | JP3841646B2 (pt) |
AT (1) | ATE278675T1 (pt) |
BR (1) | BR0100878A (pt) |
CA (1) | CA2340138C (pt) |
DE (1) | DE60106117T2 (pt) |
DK (1) | DK1134215T3 (pt) |
ES (1) | ES2225422T3 (pt) |
PT (1) | PT1134215E (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
EP1373199A4 (en) * | 2001-03-15 | 2004-04-07 | Bristol Myers Squibb Pharma Co | SPIROCYCLIC BETA-AMINOACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND THE CONVERSION ENZYME OF TNF-ALPHA (TAGE) |
JPWO2003080041A1 (ja) * | 2002-03-27 | 2005-07-21 | 塩野義製薬株式会社 | 変形性関節症治療薬 |
CA2492035A1 (en) * | 2002-07-11 | 2004-01-15 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
TW200410923A (en) * | 2002-10-17 | 2004-07-01 | Ono Pharmaceutical Co | Therapeutic agent for chronic obstructive pulmonary disease |
ATE457716T1 (de) | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
KR20110140139A (ko) * | 2003-08-29 | 2011-12-30 | 오노 야꾸힝 고교 가부시키가이샤 | S1p 수용체 결합능을 갖는 화합물 및 그 의약 용도 |
DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
US20070258941A1 (en) * | 2006-05-02 | 2007-11-08 | Pfister Brian E | Methods and compositions for remediation of disc herniation by modifying structure |
ATE509956T1 (de) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
ZA966885B (en) | 1995-08-22 | 1998-02-16 | Du Pont Merck Pharma | Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors. |
US5612074A (en) | 1995-12-21 | 1997-03-18 | Leach; Robin L. | Nutrient fortified food bar |
NZ333303A (en) | 1996-07-18 | 2000-06-23 | Lawrence Alan Reiter | Phosphinate based inhibitors of matrix metalloproteases |
BR9711223A (pt) | 1996-08-23 | 1999-08-17 | Pfizer | Derivados de cido arilsulfonilamino-hidrox mico |
AU731319B2 (en) | 1996-08-28 | 2001-03-29 | Procter & Gamble Company, The | Heterocyclic metalloprotease inhibitors |
ATE226193T1 (de) | 1996-08-28 | 2002-11-15 | Procter & Gamble | Substituierte zyklische amine als metalloproteaseinhibitoren |
HUP0000657A3 (en) | 1997-02-11 | 2000-10-30 | Pfizer | N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them |
JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用 |
GT199900044A (es) | 1998-04-10 | 2000-09-14 | Procedimientos para preparar haluros de fenoxifenilsulfonilo. | |
PA8469601A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Procedimiento para alquilar sulfonamidas impedidas estericamente |
PA8469301A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Procedimientos para la preparacion de acidos hidroxamicos. |
AU4692399A (en) | 1998-06-17 | 2000-01-05 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
ES2242402T3 (es) | 1998-08-12 | 2005-11-01 | Pfizer Products Inc. | Inhibidores de tace. |
EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
-
2000
- 2000-12-05 US US09/730,302 patent/US6458822B2/en not_active Expired - Fee Related
-
2001
- 2001-02-20 JP JP2001043556A patent/JP3841646B2/ja not_active Expired - Fee Related
- 2001-03-05 DE DE60106117T patent/DE60106117T2/de not_active Expired - Fee Related
- 2001-03-05 DK DK01301989T patent/DK1134215T3/da active
- 2001-03-05 AT AT01301989T patent/ATE278675T1/de not_active IP Right Cessation
- 2001-03-05 ES ES01301989T patent/ES2225422T3/es not_active Expired - Lifetime
- 2001-03-05 PT PT01301989T patent/PT1134215E/pt unknown
- 2001-03-05 EP EP01301989A patent/EP1134215B1/en not_active Expired - Lifetime
- 2001-03-09 CA CA002340138A patent/CA2340138C/en not_active Expired - Fee Related
- 2001-03-12 BR BR0100878-1A patent/BR0100878A/pt not_active Application Discontinuation
-
2002
- 2002-04-05 US US10/117,539 patent/US20020147224A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2340138C (en) | 2005-10-18 |
DK1134215T3 (da) | 2005-01-10 |
ES2225422T3 (es) | 2005-03-16 |
PT1134215E (pt) | 2004-12-31 |
US6458822B2 (en) | 2002-10-01 |
US20010041710A1 (en) | 2001-11-15 |
EP1134215B1 (en) | 2004-10-06 |
JP3841646B2 (ja) | 2006-11-01 |
US20020147224A1 (en) | 2002-10-10 |
JP2001261656A (ja) | 2001-09-26 |
DE60106117D1 (de) | 2004-11-11 |
EP1134215A1 (en) | 2001-09-19 |
DE60106117T2 (de) | 2005-10-13 |
ATE278675T1 (de) | 2004-10-15 |
CA2340138A1 (en) | 2001-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0100878A (pt) | Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matriz | |
DE69939752D1 (de) | 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors | |
IT1314184B1 (it) | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo | |
DE69813571D1 (de) | 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten | |
ATE208397T1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
ATE260255T1 (de) | 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate | |
NO20024042D0 (no) | Aryl-fusjonerte azapolysykliske forbindelser | |
MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
NZ325559A (en) | Metalloproteinase inhibitors, pharmaceutical compoMetalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical usitions containing them and their pharmaceutical uses, and methods and intermediates useful for theises, and methods and intermediates useful for their preparation r preparation | |
DK0898562T3 (da) | Hydroxamsyrederivater til anvendelse ved behandling af sygdomme relateret til bindevævsdegenerering | |
MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
EA200801261A1 (ru) | Фармацевтические композиции на основе галлия и способы | |
ATE509905T1 (de) | Benzamidderivate | |
TW363056B (en) | Inhibition of matrix metalloproteases by substituted phenethyl compounds | |
CA2392271A1 (en) | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | |
DK1179342T3 (da) | Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse | |
NO20032314L (no) | Nye desloratadinsalter, fremgangsmåte for deres syntese og farmasöytiske preparater derav | |
AU2002254124A1 (en) | Aryl-n-cyanoguanidines and methods related thereto | |
EP1386608A4 (en) | MEANS FOR THE TREATMENT OF GLOMERULOPATHY | |
WO2003053331A3 (en) | Protease inhibitors | |
JP3919844B2 (ja) | エポキシコハク酸誘導体 | |
MA30882B1 (fr) | Derives d'acides vinylogues en tant qu'inhibiteur de la chymase | |
MY133525A (en) | Ethyl(2s)-2-(naphthalene-1-sulfonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionate hemifumarate, a process and intermediates for its preparation, and its use asa pharmaceutical | |
TH62460A (th) | ตัวยับยั้งเมทัลโลโพรทีเอสที่ได้รับการแทนที่ที่ n ซึ่งมีโซ่ข้างเฮเทอโรไซคลิค |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |